Navigation Links
New test takes guesswork out of diagnosing early-stage Alzheimer's disease
Date:3/25/2010

A new test developed by Japanese scientists may revolutionize how and when physicians diagnose Alzheimer's disease. According to a research report published online in The FASEB Journal (http://www.fasebj.org), the new test measures proteins in the spinal fluid known to be one of the main causes of brain degeneration and memory impairment in Alzheimer's patients: high molecular weight A-Beta oligomers. This tool, once fully implemented, would allow physicians to diagnose and treat Alzheimer's disease in its early stages, a time when diagnosing the disease is very difficult.

"Alzheimer's disease is a growing problem, due to aging of the population in all developed countries," said Takahiko Tokuda, M.D., Ph.D., a researcher from the Department of Neurology at the Kyoto Prefectural University of Medicine Graduate School of Medical Science in Japan who was involved in the work. "We hope that our new diagnostic test will, in the future, significantly improve the lives of people with Alzheimer's disease, and lead to much better ways of treating this devastating disorder."

Scientists developed a tool (enzyme-linked immunosorbent assay) that specifically measures A-Beta oligomers. They then compared the levels of these protein aggregates in human cerebrospinal fluid samples among three groups of people: 1) patients with diagnosed Alzheimer's disease; 2) patients with mild cognitive impairment who went on to develop Alzheimer's disease; and 3) a control group with no symptoms of Alzheimer's disease. Results showed that the levels of the a fragments being measured directly correlated to the extent of memory impairment, with the highest levels found in those with confirmed Alzheimer's and intermediate levels in those with mild cognitive impairment. This shows that by measuring the levels of A-Beta oligomers in cerebrospinal fluid, physicians may be able to identify Alzheimer's disease before it can be clinically diagnosed using current methods.

"Baby boomers are getting older and Alzheimer's disease will have a tremendous impact on the memory of a generation and the lives of its children," said Gerald Weissmann, M.D., Editor-in-Chief of The FASEB Journal. "This test is not only useful for the early detection of Alzheimer's disease, but promises to be a marker for the efficacy of newer treatments that are already on the drawing board."


'/>"/>

Contact: Cody Mooneyhan
cmooneyhan@faseb.org
301-634-7104
Federation of American Societies for Experimental Biology
Source:Eurekalert

Related biology news :

1. Meteosat Third Generation takes a step forward
2. milch & zucker Takes ELISE Mobile With JobStairs iPhone App
3. It takes 2 to infect
4. Worlds largest ocean observatory takes shape
5. SIRT1 takes down tumors
6. University of Kansas graduate student researcher takes aim at deadly brain tumors
7. RNA research strategy for Europe takes shape
8. It takes a genome: How a clash between our genes and modern life is making us sick
9. New models question old assumptions about how many molecules it takes to control cell division
10. It takes 2 to tango
11. Small satellite takes on large thunderstorms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/26/2017)...  Acuity Market Intelligence today released the 2017 ...  Acuity characterizes 2017 as a "breakout" year for ... a new understanding of the potential benefits these ... identity are often perceived as threats to privacy ... of Acuity Market intelligence. "However, taken together these ...
(Date:1/24/2017)... 24, 2017  It sounds simple and harmless—an ... monitors vital signs and alerts parents on their ... saturation level drops. But pediatric experts argue that ... with no evidence of medical benefits, especially to ... aggressively to parents of healthy babies, promising peace ...
(Date:1/19/2017)... , January 19, 2017 According to a new ... and Forecast, 2014 - 2022," the global biometric sensor market is expected to ... to 2022. In 2015, Asia-Pacific dominated the global market ... private sectors. Continue Reading ... ...
Breaking Biology News(10 mins):
(Date:2/25/2017)... ... February 25, 2017 , ... ... Clinical Trials in an ongoing effort to create meaningful change by increasing ... pharmaceutical research with emphasis on consumers and patients’ mental health well-being. , Both ...
(Date:2/24/2017)... , Feb. 24, 2017 Provectus Biopharmaceuticals, ... the "Company"), a clinical-stage oncology and dermatology biopharmaceutical ... deadline to participate in its previously announced rights ... of shares of common stock and Series C ... of listed warrants. As previously ...
(Date:2/24/2017)... Blood Corporation (NYSE: CO ) ("CCBC" or ... laboratory testing, hematopoietic stem cell processing and stem cell ... the third quarter and first nine months of fiscal ... Quarter of Fiscal 2017 Highlights Revenues ... 18.6% to RMB200.9 million ($28.9 million). ...
(Date:2/24/2017)... , Feb. 24, 2017  OncoSec Medical Incorporated ... immunotherapies, will host a Key Opinion Leader event to ... an oral and poster presentation at the upcoming 2017 ... The KOL event will be held in-person and via ... EST / 9:00 AM PST at the Lotte New ...
Breaking Biology Technology: